AT TRINITY, we are dedicated to making safer and more effective combination therapies that are more accessible to those suffering from chronic and neuropathic pain.
We develop COMBINATION THERAPY drugs using our expertise that enables high therapeutic efficacy and minimal toxicity for treating chronic and neuropathic pain in humans.
Learn More >
Trinity Laboratories announces the issuance of core patent US 8,604,082 for the treatment of premature ejaculation in humans in the US. The core patent is pending in the EU and Japan.